Novavax, Inc. (NVAX)
8.855
-0.08
(-0.95%)
USD |
NASDAQ |
Aug 24, 16:00
8.86
0.00 (0.00%)
After-Hours: 20:00
Novavax Enterprise Value : 1.051B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.051B |
| August 20, 2026 | 965.73M |
| August 19, 2026 | 1.027B |
| August 18, 2026 | 884.97M |
| August 17, 2026 | 908.04M |
| August 14, 2026 | 904.74M |
| August 13, 2026 | 919.58M |
| August 12, 2026 | 889.91M |
| August 11, 2026 | 888.26M |
| August 10, 2026 | 878.37M |
| August 07, 2026 | 888.26M |
| August 06, 2026 | 853.65M |
| August 05, 2026 | 847.06M |
| August 04, 2026 | 840.47M |
| August 03, 2026 | 799.26M |
| July 31, 2026 | 784.43M |
| July 30, 2026 | 804.21M |
| July 29, 2026 | 787.72M |
| July 28, 2026 | 792.67M |
| July 27, 2026 | 812.45M |
| July 24, 2026 | 807.50M |
| July 23, 2026 | 867.66M |
| July 22, 2026 | 881.67M |
| July 21, 2026 | 908.86M |
| July 20, 2026 | 876.73M |
| Date | Value |
|---|---|
| July 17, 2026 | 931.11M |
| July 16, 2026 | 936.06M |
| July 15, 2026 | 967.37M |
| July 14, 2026 | 965.73M |
| July 13, 2026 | 1.046B |
| July 10, 2026 | 1.116B |
| July 09, 2026 | 1.127B |
| July 08, 2026 | 1.119B |
| July 07, 2026 | 1.137B |
| July 06, 2026 | 1.119B |
| July 02, 2026 | 1.183B |
| July 01, 2026 | 1.137B |
| June 30, 2026 | 1.131B |
| June 29, 2026 | 1.044B |
| June 26, 2026 | 964.80M |
| June 25, 2026 | 912.18M |
| June 24, 2026 | 968.09M |
| June 23, 2026 | 984.53M |
| June 22, 2026 | 984.53M |
| June 18, 2026 | 1.006B |
| June 17, 2026 | 1.067B |
| June 16, 2026 | 1.017B |
| June 15, 2026 | 1.019B |
| June 12, 2026 | 964.80M |
| June 11, 2026 | 989.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 54.06B |
| Merck & Co., Inc. | 423.37B |
| Pfizer Inc. | 211.77B |
| Recursion Pharmaceuticals, Inc. | 1.385B |
| Agenus, Inc. | 609.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -53.39M |
| Revenue (Quarterly) | 56.70M |
| Total Expenses (Quarterly) | 110.08M |
| EPS Diluted (Quarterly) | -0.3244 |
| Gross Profit Margin (Quarterly) | 77.70% |
| Profit Margin (Quarterly) | -94.16% |
| Earnings Yield | -17.20% |
| Normalized Earnings Yield | -10.37 |